Corifollitropin alfa is a new recombinant gonadotrophin with a different pharmacokinetic profile but similar pharmacodynamic properties to conventional recombinant FSH. A single dose of corifollitropin alfa sustains multiple follicular development during the first 7 days of ovarian stimulation. This review is based on results of phase II and III trials testing the selected dose of 150 μg corifollitropin alfa in subjects >60 kg and 100 μg in subjects ≤60 kg. Exposure to corifollitropin alfa is inversely related to bodyweight. The selected doses of 100 and 150 μg in subjects weighing ≤60 and >60 kg, respectively, provide, on average, equal drug exposure producing similar ovarian responses in terms of the number of growing follicles, serum oestradiol, inhibin B and number of oocytes retrieved. Clinicians treating IVF patients with corifollitropin alfa should alter their treatment paradigm as a lower or higher dose than recommended according to body weight does not affect the ovarian response, which depends mainly on the ovarian reserve. After decades of daily dosing with FSH preparations, corifollitropin alfa allows a simpler IVF treatment regime with fewer injections. Successful use of corifollitropin alfa requires assessment of patient suitability and dosing before the start of stimulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.rbmo.2011.04.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of a Long-Acting Follicle-Stimulating Hormone Using Serum Albumin Fab-Associated Technology for Female Infertility.
Endocrinol Metab (Seoul)
December 2024
Department of Internal Medicine, Institute of Endocrine Research, Yonsei University College of Medicine, Seoul, Korea.
Background: Recombinant human follicle-stimulating hormone (rhFSH) is commonly used to treat female infertility, but its short half-life necessitates multiple doses. Even corifollitropin alfa, with an extended half-life, requires supplementary injections of rhFSH after 7 days. This study aimed to develop and evaluate a long-acting follicle-stimulating hormone (FSH) formulation using anti-serum albumin Fab-associated (SAFA) technology to avoid additional injections and enhance ovarian function.
View Article and Find Full Text PDFTherapeutic management in women with a diminished ovarian reserve: a systematic review and meta-analysis of randomized controlled trials.
Fertil Steril
September 2024
Department of Public Health, University of Naples Federico II, Naples, Italy.
Article Synopsis
- The clinical management of women with diminished ovarian reserve (DOR) poses challenges, particularly due to inconsistent definitions of DOR across studies.
- This research aims to evaluate various adjuvant treatments for women with DOR based on the POSEIDON criteria, analyzing data from numerous studies published until June 2024.
- The analysis includes 38 randomized controlled trials, identifying testosterone supplementation as a treatment associated with higher live birth rates in women with DOR compared to those who did not receive supplementation.
Reproductive outcome after in vitro fertilization in endometriosis - key factors and implications.
J Med Life
March 2024
Department of Obstetrics and Gynecology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Endometriosis is a benign chronic disease with a major impact on a woman's quality of life, mainly due to painful physical symptoms. Endometriosis is also a common cause of infertility caused by low ovarian reserve, distorted pelvic anatomy, and severe local inflammation with a direct negative impact on the quality of oocytes, embryos, and endometrium. We conducted a retrospective study between January 2019 and December 2023, including women with a history of surgery for endometriosis who underwent in vitro fertilization (IVF) to achieve pregnancy.
View Article and Find Full Text PDFPretreatment with luteal estradiol for programming antagonist cycles compared to no pretreatment in advanced age women stimulated with corifollitropin alfa: a non-inferiority randomized controlled trial.
Hum Reprod
September 2024
Reproductive Medicine, Clinique Mutualiste La Sagesse, Rennes, France.
Study Question: Does luteal estradiol (E2) pretreatment give a similar number of retrieved oocytes compared to no-pretreatment in advanced-aged women stimulated with corifollitropin alfa in an antagonist protocol?
Summary Answer: Programming antagonist cycles with luteal E2 gave similar number of retrieved oocytes compared to no-pretreatment in women aged 38-42 years.
What Is Known Already: Programming antagonist cycles with luteal E2 pretreatment is a valuable tool to organize the IVF procedure better and is safe without any known impact on cycle outcome. However, variable effects were observed on the number of retrieved oocytes depending on the treated population.
Superovulating cattle with corifollitropin-alpha, a long-acting recombinant human FSH (rhFSH): Dose-response, half-life, effects on the ovaries, and embryo outcomes.
Theriogenology
September 2024
Universidade Prof. Edson Antônio Velano, Alfenas, MG, 37130-000, Brazil.
The aim of this study was to evaluate the superestimulatory and superovulatory responses of cattle treated with corifollitropin-alpha, a long-acting human recombinant FSH (rhFSH). In the first and second experiments, we used Nelore (Bos indicus) heifers previously submitted to follicular wave suppression by active immunization against GnRH. In Experiment 1 (a dose-response study), heifers (n = 20) were randomly allocated into five groups, which received placebo (saline) or a single sc dose of 7.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!